DFO
REGN icon

Duquesne Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Duquesne Family Office’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-35,582
Closed -$19.9M – 71
2020
Q3 		$19.9M Sell
35,582
-3,118
-8% -$1.89M 0.58% 37
2020
Q2 		$24.1M Buy
+38,700
New +$22M 0.74% 32
2017
Q4 		– Sell
-31,800
Closed -$14.2M – 47
2017
Q3 		$14.2M Buy
+31,800
New +$15.1M 0.65% 31

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Duquesne Family Office's REGN Position: Q4 2020 in Review

Duquesne Family Office sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 35,582 shares — an estimated $19.9M sold.

Duquesne Family Office first reported a position in REGN in Q3 2017 and held it in 3 quarters. The position peaked at $24.1M in Q2 2020. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Duquesne Family Office reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Duquesne Family Office sold 35,582 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $19.9M.
  • Duquesne Family Office first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Duquesne Family Office's Regeneron Pharmaceuticals position peaked at $24.1M in Q2 2020.
  • 903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Duquesne Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.